(function(){
			var content_array=["<p><b>About Lonza<\/b> <br \/>Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector. <\/p> \n<p>Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately <span id=\"spanHghlt3594\">16,000<\/span> full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of <span class=\"xn-money\">CHF 5.4 billion<\/span> with a CORE EBITDA of <span class=\"xn-money\">CHF 1.7 billion<\/span> in Full-Year 2021. Find out more at <a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/Uzp6Qwss\" rel=\"nofollow\">www.lonza.com<\/a>. <\/p> \n<p><b>About HaemaLogiX Ltd - <\/b><a target=\"_blank\" href=\"https:\/\/t.prnasia.com\/t\/I6jMCcF1\" rel=\"nofollow\"><b>www.haemalogix.com<\/b><\/a><b>:<\/b> &nbsp;<br \/>Formed in 2014, HaemaLogiX is a public unlisted biotech company researching antibody therapies for multiple myeloma. Multiple myeloma is a haematological (blood) cancer of plasma cells (B cells) that can cause focused damage to a patient’s bone marrow. Multiple myeloma is considered treatable but generally incurable. The HaemaLogiX team has a wide range and depth of experience in antibody research, nonclinical &amp; clinical development, manufacturing and commercialisation. The Scientific Advisory Board (SAB) members are internationally recognised experts in monoclonal antibody therapies and haematology. Our current research and clinical trial partners are global leaders in Multiple Myeloma and AL Amyloidosis therapy. HaemaLogiX is located in <span class=\"xn-location\">Sydney, Australia<\/span>.<\/p> \n<p><b>Additional Information and Disclaimer<\/b> <br \/>Lonza Group Ltd has its headquarters in <span class=\"xn-location\">Basel, Switzerland<\/span>, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. <br \/><\/p> \n<p>Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release. <br \/><\/p>"];
			$("#dvExtra").html(content_array[0]);})();